Baxter aims to divide and conquer


US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies.

The biopharma unit will include Baxter’s existing plasma- and recombinant protein-based drugs for haemophilia, along with treatments for other blood-related conditions. The company stated that it will look to add to its pipeline of treatments and diagnostics for bleeding disorders through collaborations and acquisitions.

The remaining ‘medical products’ outfit includes Baxter’s dialysis equipment, as well as intravenous drug delivery systems, anaesthetics and surgical equipment. That business will aim to grow by increasing its geographical reach and streamlining costs.


Related Content

Baxter to pay $4bn for dialysis firm

6 December 2012 Business

news image

Gambro makes products for hemodialysis and continuous renal replacement therapy

10 years ago - Alain Baxter

1 May 2012 Flashback

news image

British Olympic skier Alain Baxter had his bronze medal taken away after a post-race drug test showed traces of methamphetami...

Most Read

Refining Avogadro’s number on way to new kilo

21 July 2015 Research

news image

Most precise value yet reduces uncertainty down to 20 atoms in a billion

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe

Most Commented

Caramel colour in soft drinks linked to cancer

26 February 2015 News and Analysis

news image

Regulatory bodies and researchers sceptical of study on 4-MEI found in food colour

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe